Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Cross Below 200-Day Moving Average of $6.62

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $6.62 and traded as low as $4.24. Eagle Pharmaceuticals shares last traded at $4.41, with a volume of 51,307 shares trading hands.

Eagle Pharmaceuticals Trading Up 0.2 %

The firm has a market capitalization of $57.27 million, a PE ratio of 3.74 and a beta of 0.46. The firm’s fifty day moving average price is $5.21 and its 200 day moving average price is $6.62.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its stake in shares of Eagle Pharmaceuticals by 623.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock worth $36,000 after buying an additional 5,896 shares during the last quarter. Headlands Technologies LLC grew its stake in shares of Eagle Pharmaceuticals by 263.4% during the 3rd quarter. Headlands Technologies LLC now owns 2,326 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 1,686 shares during the period. DGS Capital Management LLC purchased a new position in shares of Eagle Pharmaceuticals during the 4th quarter valued at approximately $60,000. Aristides Capital LLC acquired a new position in shares of Eagle Pharmaceuticals in the 4th quarter valued at $86,000. Finally, Oxford Asset Management LLP purchased a new stake in Eagle Pharmaceuticals during the fourth quarter worth $101,000. 85.36% of the stock is owned by institutional investors and hedge funds.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.